Hospital del Mar -ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

    Biomedicine and Pharmacotherapy, Vol. 176

  2. Hallmarks of pancreatic cancer: spotlight on TAM receptors

    eBioMedicine, Vol. 107

  3. Validation of ZIP4 as a tumour-associated antigen for nanotargeting

    Journal of Drug Targeting

2023

  1. Electrochemical immunoplatform to help managing pancreatic cancer

    Journal of Electroanalytical Chemistry, Vol. 935

  2. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

    Cells, Vol. 12, Núm. 6

  3. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy

    Nature communications, Vol. 14, Núm. 1, pp. 746

2022

  1. Distinct roles for PARP-1 and PARP-2 in c-Myc–driven B-cell lymphoma in mice

    Blood, Vol. 139, Núm. 2, pp. 228-239

  2. Electrochemical immunosensing of Growth arrest-specific 6 in human plasma and tumor cell secretomes

    Electrochemical Science Advances, Vol. 2, Núm. 4

  3. Exploring the Role of Galectins in Cancer : In Vitro and In Vivo Approaches

    Methods in Molecular Biology (Humana Press Inc.), pp. 685-711

  4. Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells

    Cancers, Vol. 14, Núm. 4

  5. Sialyltransferase Inhibitor Ac53FaxNeu5Ac Reverts the Malignant Phenotype of Pancreatic Cancer Cells, and Reduces Tumor Volume and Favors T-Cell Infiltrates in Mice

    Cancers, Vol. 14, Núm. 24

  6. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

    eBioMedicine, Vol. 75

2021

  1. CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease

    Science Translational Medicine, Vol. 13, Núm. 613

  2. Electrochemical immunosensing of st2: A checkpoint target in cancer diseases

    Biosensors, Vol. 11, Núm. 6

2020

  1. Galectins in the Tumor Microenvironment: Focus on Galectin-1

    Advances in Experimental Medicine and Biology (Springer), pp. 17-38

  2. Impact of galectins in resistance to anticancer therapies

    Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6086-6101

  3. Knockdown of α2,3-sialyltransferases impairs pancreatic cancer cell migration, invasion and e-selectin-dependent adhesion

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-24

  4. The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer

    Cells, Vol. 9, Núm. 3

2019

  1. Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

    Nature Reviews Urology, Vol. 16, Núm. 7, pp. 433-445